Is LTMCF or MRK a better dividend investment in 2026?

LTMCF currently yields 470.04% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: LTMCF offers higher current income.

What is the dividend yield difference between LTMCF and MRK?

LTMCF has a forward dividend yield of 470.04% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 467.28 percentage points.

Home › Compare › LTMCF vs MRK

LTMCF vs MRK: Dividend Comparison 2026

LTMCF yields 470.04% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 LTMCF wins by $38201.05M in total portfolio value

INVESTMENT

TIME HORIZON10 years

LTMCF

● Live price

470.04%

Share price

$0.43

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$38201.11M

Annual income

$26,930,421,482.70

Full LTMCF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — LTMCF vs MRK

📍 LTMCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	LTMCF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, LTMCF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

LTMCF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LTMCF

Annual income on $10K today (after 15% tax)

$39,953.00/yr

After 10yr DRIP, annual income (after tax)

$22,890,858,260.30/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, LTMCF beats the other by $22,890,849,931.88/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LTMCF + MRK for your $10,000?

LTMCF: 50%MRK: 50%

100% MRK50/50100% LTMCF

Portfolio after 10yr

$19100.58M

Annual income

$13,465,215,640.42/yr

Blended yield

70.50%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LTMCF

No analyst data

Altman Z

12.4

Piotroski

2/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LTMCF buys

MRK buys

No recent congressional trades found for LTMCF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricLTMCFMRK

Forward yield	470.04% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$38201.11M ✓	$56.8K
Annual income after 10y	$26,930,421,482.70 ✓	$9,798.13
Total dividends collected	$37206.70M ✓	$28.9K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: LTMCF vs MRK ($10,000, DRIP)

Year	LTMCF Portfolio	LTMCF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$57,704	$47,003.53	$11,206	$366.19	+$46.5K → LTMCF
2	$315,226	$253,483.09	$12,650	$502.35	+$302.6K → LTMCF
3	$1,631,442	$1,294,150.32	$14,407	$694.19	+$1.62M → LTMCF
4	$8,005,303	$6,259,659.86	$16,585	$967.82	+$7.99M → LTMCF
5	$37,271,701	$28,706,026.65	$19,342	$1,363.89	+$37.25M → LTMCF
6	$164,788,863	$124,908,143.08	$22,913	$1,947.19	+$164.77M → LTMCF
7	$692,449,946	$516,125,862.62	$27,662	$2,823.89	+$692.42M → LTMCF
8	$2,767,821,677	$2,026,900,234.99	$34,159	$4,173.35	+$2767.79M → LTMCF
9	$10,533,354,933	$7,571,785,738.22	$43,337	$6,308.80	+$10533.31M → LTMCF
10	$38,201,111,261	$26,930,421,482.70	$56,776	$9,798.13	+$38201.05M → LTMCF

LTMCF vs MRK: Complete Analysis 2026

LTMCF — Stock

Lithium Chile Inc. engages in the acquisition and development of mining properties in Chile and Argentina. The company explores for gold, silver, and copper deposits. It holds interests in a lithium property portfolio consisting of approximately 91,861 hectares of exploration claims in Chile and Argentina; and a copper-gold property portfolio comprising approximately 21,329 hectares of exploration claims in Chile. The company was formerly known as Kairos Capital Corporation and changed its name to Lithium Chile Inc. in December 2017. Lithium Chile Inc. was incorporated in 2010 and is headquartered in Calgary, Canada.

Full LTMCF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this LTMCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LTMCF vs SCHD LTMCF vs JEPI LTMCF vs O LTMCF vs KO LTMCF vs MAIN LTMCF vs JNJ LTMCF vs ABBV LTMCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.